199 related articles for article (PubMed ID: 24350812)
1. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
Johnson KA; Barry E; Lambert D; Fitzgerald M; McNicholas F; Kirley A; Gill M; Bellgrove MA; Hawi Z
J Child Adolesc Psychopharmacol; 2013 Dec; 23(10):655-64. PubMed ID: 24350812
[TBL] [Abstract][Full Text] [Related]
2. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.
Nemoda Z; Angyal N; Tarnok Z; Gadoros J; Sasvari-Szekely M
Neuropharmacology; 2009 Dec; 57(7-8):731-3. PubMed ID: 19733552
[TBL] [Abstract][Full Text] [Related]
3. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
[TBL] [Abstract][Full Text] [Related]
4. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.
Bruxel EM; Salatino-Oliveira A; Genro JP; Zeni CP; Polanczyk GV; Chazan R; Rohde LA; Hutz MH
Pharmacogenomics J; 2013 Oct; 13(5):476-80. PubMed ID: 22688218
[TBL] [Abstract][Full Text] [Related]
5. Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.
Angyal N; Horvath EZ; Tarnok Z; Richman MJ; Bognar E; Lakatos K; Sasvari-Szekely M; Nemoda Z
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):122-128. PubMed ID: 29374517
[TBL] [Abstract][Full Text] [Related]
6. High-Dose Methylphenidate and Carboxylesterase 1 Genetic Variability in Patients With Attention-Deficit/Hyperactivity Disorder: A Case Series.
Westerkamp AC; Pereira RR; Huitema VR; Kouwert EAM; Matic M; van Schaik RHN; Punt N; Schoevers RA; Touw DJ
J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):35-38. PubMed ID: 37851403
[TBL] [Abstract][Full Text] [Related]
7. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.
Kim BN; Kim JW; Cummins TD; Bellgrove MA; Hawi Z; Hong SB; Yang YH; Kim HJ; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
J Clin Psychopharmacol; 2013 Jun; 33(3):356-62. PubMed ID: 23609393
[TBL] [Abstract][Full Text] [Related]
8. [Response With Methylphenidate to ADHD-Like Symptoms in Pervasive Developmental Disorder: Does CES-1 Enzyme Gene Polymorphism Have a Role?].
Akyol Ardıç Ü; Ercan ES; Aygüneş D; Yüce D; Durak S; Kosova B
Turk Psikiyatri Derg; 2017; 28(2):89-94. PubMed ID: 29192941
[TBL] [Abstract][Full Text] [Related]
9. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
Lakić A
Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder.
Mick E; McGough JJ; Middleton FA; Neale B; Faraone SV
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):466-72. PubMed ID: 21130132
[TBL] [Abstract][Full Text] [Related]
12. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
Işeri E; Kiliç BG; Senol S; Karabacak NI
Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
Kim SW; Lee JH; Lee SH; Hong HJ; Lee MG; Yook KH
J Clin Psychopharmacol; 2013 Aug; 33(4):491-8. PubMed ID: 23771192
[TBL] [Abstract][Full Text] [Related]
14. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.
Leddy JJ; Waxmonsky JG; Salis RJ; Paluch RA; Gnagy EM; Mahaney P; Erbe R; Pelham WE; Epstein LH
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):127-36. PubMed ID: 19364291
[TBL] [Abstract][Full Text] [Related]
15. Caregiver survey of pharmacotherapy to treat attention deficit/hyperactivity disorder in individuals with Williams syndrome.
Martens MA; Seyfer DL; Andridge RR; Foster JE; McClure KE; Coury DL
Res Dev Disabil; 2013 May; 34(5):1700-9. PubMed ID: 23500164
[TBL] [Abstract][Full Text] [Related]
16. High Familial Correlation in Methylphenidate Response and Side Effect Profile.
Gazer-Snitovsky M; Brand-Gothelf A; Dubnov-Raz G; Weizman A; Gothelf D
J Atten Disord; 2019 Jan; 23(2):135-139. PubMed ID: 25899797
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD.
Lee SH; Kim SW; Lee MG; Yook KH; Greenhill LL; Fradin KN; Hong HJ
Psychiatry Res; 2011 Apr; 186(2-3):338-44. PubMed ID: 20863575
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
Moungnoi P; Maipang P
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
[TBL] [Abstract][Full Text] [Related]
19. Methylphenidate dosing: twice daily versus three times daily.
Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
[TBL] [Abstract][Full Text] [Related]
20. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
